Enzalutamide approved for metastatic castration-sensitive PCa
The FDA has approved a supplemental New Drug Application or enzalutamide (XTANDI) for the treatment of patients with metastatic castration-sensitive prostate cancer.
Related Articles
Study findings point to do disparities in pain management for kidney stones
“We found that female patients, Black patients, and patients with non-private insurance had a decreased odds of receiving opioids,” says Hailey Frye.
Ruchika Talwar, MD, discusses ongoing drug shortages in urology
“A key point is the supply chain is very fragile, and there’s not really a good financial incentive to make these drugs,” says Ruchika Talwar,…
The Contemporary Treatment Landscape of mCRPC
Panelists discuss how the evolving treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) encompasses multiple therapeutic options including novel hormonal agents, chemotherapy, and targeted therapies…
Dr Louise Kostos discusses PSA kinetics in mHSPC
“Personally, I think monitoring and analyzing PSA kinetics is a great one because it’s cheap and it’s readily available,” says Dr Louise Kostos.
FDA greenlights trial of orellanine in metastatic renal cell carcinoma
The study will evaluate the investigational drug product ONC175 (orellanine) in patients with metastatic clear cell or papillary renal cell carcinoma.
Laura Bukavina, MD, on trial of radiation with concurrent sacituzumab govitecan in MIBC
The trial is assessing the safety and tolerability of adaptive radiation therapy with concurrent sacituzumab govitecan in patients with MIBC.
Exercise may improve erectile function in men with prostate cancer
“The study suggests that exercise would be an effective intervention for men with prostate cancer who express concern about sexual dysfunction, and that exercise medicine…
Michael R. Folkert, MD, PhD, discusses real-world outcomes with spacer in prostate cancer
“4 years following radiation therapy, there is a 25% lower hazard of bowel disorders and a 46% lower hazard of related procedures [in patients who…
What determines the optimal urinary diversion?
“Ultimately, there is no ‘right choice’ when it comes to urinary diversion,” writes Anne K. Schuckman, MD.
Kidney stone prevalence is increasing in women, study findings show
The overall prevalence of kidney stones overall remained stable, with a notable increase observed among women.